Transaction DateRecipientSharesTypePriceValue
13th October 2020Mark T Iwicki7,840Sale back to the issuer$34.50$270,480.00
10th October 2020Mark T Iwicki39,567Disposition due to a tender of shares in a change of control transaction$34.50$1,365,061.50
8th October 2020Capital Management, L.P. Ra167,661Open or private sale$50.69$8,498,065.45
7th October 2020Capital Management, L.P. Ra98,597Open or private sale$50.95$5,023,527.01
30th September 2020Capital Management, L.P. Ra124,656Open or private sale$50.27$6,265,871.24
29th September 2020Capital Management, L.P. Ra950,000Open or private purchase$18.00$17,100,000.00
29th September 2020Capital Management, L.P. Ra760,265Conversion of derivative$0.00
29th September 2020Capital Management, L.P. Ra80,707Open or private sale$52.08$4,202,986.51
21st September 2020Capital Management, L.P. Ra660,000Open or private purchase$19.00$12,540,000.00
21st September 2020Capital Management, L.P. Ra2,145,045Conversion of derivative$0.00
Kala Pharmaceuticals
Kala Pharmaceuticals logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.


Kala Pharmaceuticals, Inc. focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based Mucus Penetrating Particles. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Watertown, MA.


Ticker: KALA
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1479419
Employees: 136
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $128 M (0%)
Inventory, Net: $6 M (0%)
Assets, Current: $197 M (86%)
Property, Plant and Equipment, Net: $3 M (9%)
Assets: $246 M (59%)
Accounts Payable, Current: $2 M (-38%)
Accrued Liabilities, Current: $14 M (0%)
Liabilities, Current: $17 M (-31%)
Long-term Debt, Excluding Current Maturities: $72 M (0%)
Liabilities: $117 M (-6%)
Common Stock, Value, Issued: $56 Th (55%)
Common Stock, Shares, Issued: $56 M (54%)
Retained Earnings (Accumulated Deficit): $341 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $17 Th (0%)
Stockholders' Equity (Parent): $129 M (0%)
Liabilities and Equity: $246 M (59%)
Research and Development: $6 M (-47%)
Operating Income/Loss: $21 M (-48%)